Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) – Equities researchers at SVB Leerink reduced their FY2024 EPS estimates for Zentalis Pharmaceuticals in a research report issued on Monday, April 11th. SVB Leerink analyst A. Berens now expects that the company will post earnings of ($3.40) per share for the year, down from their prior forecast of ($2.87). SVB Leerink currently has a “Outperform” rating and a $67.00 price target on the stock. SVB Leerink also issued estimates for Zentalis Pharmaceuticals’ FY2025 earnings at ($1.11) EPS and FY2026 earnings at $2.40 EPS.
Several other analysts also recently issued reports on the company. Stifel Nicolaus decreased their target price on Zentalis Pharmaceuticals from $94.00 to $74.00 in a research note on Monday. Oppenheimer decreased their target price on Zentalis Pharmaceuticals from $100.00 to $85.00 and set an “outperform” rating on the stock in a research note on Tuesday. Wedbush reissued an “outperform” rating on shares of Zentalis Pharmaceuticals in a research note on Friday, February 25th. Wells Fargo & Company initiated coverage on Zentalis Pharmaceuticals in a research note on Wednesday, April 6th. They issued an “overweight” rating and a $67.00 price objective on the stock. Finally, Guggenheim reduced their price objective on Zentalis Pharmaceuticals from $92.00 to $67.00 in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $82.50.
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) last issued its earnings results on Thursday, February 24th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.33) by $0.22. During the same period in the prior year, the company posted ($1.01) EPS.
A number of institutional investors and hedge funds have recently bought and sold shares of ZNTL. BlackRock Inc. boosted its holdings in Zentalis Pharmaceuticals by 18.8% during the 3rd quarter. BlackRock Inc. now owns 2,755,788 shares of the company’s stock valued at $183,645,000 after acquiring an additional 435,672 shares during the period. Perceptive Advisors LLC purchased a new position in Zentalis Pharmaceuticals during the 4th quarter valued at $36,192,000. Allspring Global Investments Holdings LLC purchased a new position in Zentalis Pharmaceuticals during the 4th quarter valued at $35,202,000. Fiera Capital Corp purchased a new position in Zentalis Pharmaceuticals during the 4th quarter valued at $30,961,000. Finally, Matrix Capital Management Company LP lifted its holdings in shares of Zentalis Pharmaceuticals by 6.1% in the 3rd quarter. Matrix Capital Management Company LP now owns 4,349,279 shares of the company’s stock worth $289,836,000 after buying an additional 248,540 shares during the period. Institutional investors own 94.61% of the company’s stock.
In other news, COO Kevin D. Bunker sold 5,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Monday, April 11th. The stock was sold at an average price of $30.55, for a total value of $152,750.00. Following the completion of the transaction, the chief operating officer now owns 135,000 shares in the company, valued at approximately $4,124,250. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Cam Gallagher sold 10,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Tuesday, April 5th. The stock was sold at an average price of $50.48, for a total value of $504,800.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 173,307 shares of company stock valued at $8,759,951. Company insiders own 21.00% of the company’s stock.
Zentalis Pharmaceuticals Company Profile (Get Rating)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- Lululemon Rises On Wave Of Price Target Increases
- The Top Is In For Infosys
- Is Nvidia (NASDAQ: NVDA) About To Rip Higher?
- 3 Stellar Steel Stocks to Buy Now
- Fasten Your Seatbelts, Fastenal Is About To Move Higher
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.